Cover Image
市場調查報告書

血管內皮層細胞生長因子B:開發中產品分析

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 368716
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
血管內皮層細胞生長因子B:開發中產品分析 Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 58 Pages
簡介

本報告提供以血管內皮層細胞生長因子B為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

血管內皮層細胞生長因子B 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Alteogen Inc.
  • Clearside BioMedical, Inc.
  • CSL Limited
  • Eli Lilly and Company
  • Formycon AG
  • Regeneron Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0779TDB

Summary

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H1 2017, outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1). The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 4 respectively. Report covers products from therapy areas Metabolic Disorders, Ophthalmology and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Choroidal Neovascularization, Diabetic Nephropathy, Lipid Disorders, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Rectal Cancer, Retinal Vein Occlusion, Retinopathy and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
  • The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)targeted therapeutics and enlists all their major and minor projects
  • The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Overview
    • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies Involved in Therapeutics Development
    • Alteogen Inc
    • CSL Ltd
    • Eli Lilly and Company
    • Formycon AG
    • Regeneron Pharmaceuticals Inc
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles
    • (aflibercept + nesvacumab) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSL-346 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ziv-aflibercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Products
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Product Development Milestones
    • Featured News & Press Releases
      • May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017
      • Feb 10, 2017: Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease
      • Dec 01, 2016: CSL Commits to New Phase I Clinical Trials of CSL346 in Australia
      • Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS
      • Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists' guidance
      • May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection
      • Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven
      • Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept)
      • Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
      • Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication
      • Sep 18, 2015: Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema
      • Jul 21, 2015: NICE gives green light to aflibercept solution for treating serious eye condition
      • Jun 26, 2015: Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan
      • Jun 02, 2015: NICE Recommended Aflibercept Solution For Injection For Treating Serious Diabetic Eye Condition In Final Draft Guidance
      • May 06, 2015: Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA in UK clinical practice
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Alteogen Inc, H1 2017
  • Pipeline by CSL Ltd, H1 2017
  • Pipeline by Eli Lilly and Company, H1 2017
  • Pipeline by Formycon AG, H1 2017
  • Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Dormant Projects, H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top